Published in:
Open Access
01-12-2012 | Research
Functional hyper-IL-6 from vaccinia virus-colonized tumors triggers platelet formation and helps to alleviate toxicity of mitomycin C enhanced virus therapy
Authors:
Julia B Sturm, Michael Hess, Stephanie Weibel, Nanhai G Chen, Yong A Yu, Qian Zhang, Ulrike Donat, Cora Reiss, Stepan Gambaryan, Georg Krohne, Jochen Stritzker, Aladar A Szalay
Published in:
Journal of Translational Medicine
|
Issue 1/2012
Login to get access
Abstract
Background
Combination of oncolytic vaccinia virus therapy with conventional chemotherapy has shown promise for tumor therapy. However, side effects of chemotherapy including thrombocytopenia, still remain problematic.
Methods
Here, we describe a novel approach to optimize combination therapy of oncolytic virus and chemotherapy utilizing virus-encoding hyper-IL-6, GLV-1h90, to reduce chemotherapy-associated side effects.
Results
We showed that the hyper-IL-6 cytokine was successfully produced by GLV-1h90 and was functional both in cell culture as well as in tumor-bearing animals, in which the cytokine-producing vaccinia virus strain was well tolerated. When combined with the chemotherapeutic mitomycin C, the anti-tumor effect of the oncolytic virotherapy was significantly enhanced. Moreover, hyper-IL-6 expression greatly reduced the time interval during which the mice suffered from chemotherapy-induced thrombocytopenia.
Conclusion
Therefore, future clinical application would benefit from careful investigation of additional cytokine treatment to reduce chemotherapy-induced side effects.